Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Reciniferatoxin
2. Resiniferatoxin
3. Rtx Diterpene
1. Resiniferatoxin
2. Chembl448382
3. Bdbm50366620
| Molecular Weight | 628.7 g/mol |
|---|---|
| Molecular Formula | C37H40O9 |
| XLogP3 | 4.5 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | 628.26723285 g/mol |
| Monoisotopic Mass | 628.26723285 g/mol |
| Topological Polar Surface Area | 121 Ų |
| Heavy Atom Count | 46 |
| Formal Charge | 0 |
| Complexity | 1330 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 7 |
| Undefined Atom Stereocenter Count | 1 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Drugs in Development
Details:
RTX (resiniferatoxin) is a small molecule which is act as TRPV1 agonist, which is investigated for the treatment of knee pain in moderate to severe osteoarthritis of the knee (OAK) patients.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Musculoskeletal Brand Name: RTX
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2023
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : RTX (resiniferatoxin) is a small molecule which is act as TRPV1 agonist, which is investigated for the treatment of knee pain in moderate to severe osteoarthritis of the knee (OAK) patients.
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 07, 2023
Details:
RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Rheumatology Brand Name: RTX
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Grünenthal Starts Phase III Trials for Resiniferatoxin in Osteoarthritis-Related Pain
Details : RTX is an intra-articular injection of resiniferatoxin developed for the treatment of pain in patients with moderate to severe pain associated with knee osteoarthritis.
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 18, 2022
Details:
The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Rheumatology Brand Name: RTX
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Shionogi
Deal Size: $670.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 04, 2022
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Rheumatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Shionogi
Deal Size : $670.0 million
Deal Type : Licensing Agreement
Grünenthal to License Osteoarthritis Pain Treatment to Shionogi in Japan in Deal of up to > $ 500...
Details : The agreement includes competitive investment commitments for launch and commercialisation. Manufacturing and supply of RTX (resiniferatoxin) to Shionogi will be carried out exclusively by Grünenthal.
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Undisclosed
August 04, 2022
Details:
Company begins enrollment in the phase 2 trial because data from the phase 1B of RTX (Resiniferatoxin) showed significant pain relief observed in patients with advanced OA disease and sustained pain relief last beyond 6 months.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Musculoskeletal Brand Name: RTX
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Company begins enrollment in the phase 2 trial because data from the phase 1B of RTX (Resiniferatoxin) showed significant pain relief observed in patients with advanced OA disease and sustained pain relief last beyond 6 months.
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 07, 2021
Details:
The Phase 1 was an ascending dose safety study in 17 patients to assess the safety and preliminary efficacy of epidural administration of resiniferatoxin for the treatment of intractable pain due to cancer.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Neurology Brand Name: RTX
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 1 was an ascending dose safety study in 17 patients to assess the safety and preliminary efficacy of epidural administration of resiniferatoxin for the treatment of intractable pain due to cancer.
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2021
Details:
The RTX clinical development program continues, with Phase 2 and 3 clinical trials planned in larger patient populations. The first Phase 2 trial will focus on identifying the recommended Phase 3 dose.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Musculoskeletal Brand Name: MTX-071
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The RTX clinical development program continues, with Phase 2 and 3 clinical trials planned in larger patient populations. The first Phase 2 trial will focus on identifying the recommended Phase 3 dose.
Brand Name : MTX-071
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 06, 2021
Details:
Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Neurology Brand Name: MTX-071
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Grunenthal
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 12, 2021
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Grunenthal
Deal Size : Undisclosed
Deal Type : Acquisition
Grünenthal Acquires Mestex and its Phase-III-Ready Investigational Medicine MTX-071 to Treat Pain...
Details : Mestex AG is a Swiss biotech company that has developed the innovative investigational medicine MTX-071 (resiniferatoxin) for the intra-articular treatment of pain associated with osteoarthritis of the knee.
Brand Name : MTX-071
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 12, 2021
Details:
The Phase 1b trial was a placebo controlled ascending dose study with an open-label extension to assess the safety and preliminary efficacy of intra-articular administration of RTX or saline control for moderate to severe pain due to osteoarthritis of the knee.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Neurology Brand Name: RTX
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 28, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The Phase 1b trial was a placebo controlled ascending dose study with an open-label extension to assess the safety and preliminary efficacy of intra-articular administration of RTX or saline control for moderate to severe pain due to osteoarthritis of th...
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 28, 2020
Details:
This multicenter, open-label study enrolled 17 adults with intractable moderate to severe cancer pain. Subjects were treated with a one-time epidural administration of RTX at escalating dose level cohorts, ranging from 0.4 µg to 25 µg in 3 ml saline, in seven cohorts.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Neurology Brand Name: RTX
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : This multicenter, open-label study enrolled 17 adults with intractable moderate to severe cancer pain. Subjects were treated with a one-time epidural administration of RTX at escalating dose level cohorts, ranging from 0.4 µg to 25 µg in 3 ml saline, i...
Brand Name : RTX
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 22, 2020
Details:
Safety in the higher dose cohort is expected to be supportive for testing RTX epidural administration in other advanced non-cancer disease related unmet clinical needs.
Lead Product(s): Resiniferatoxin
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2020
Lead Product(s) : Resiniferatoxin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Safety in the higher dose cohort is expected to be supportive for testing RTX epidural administration in other advanced non-cancer disease related unmet clinical needs.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Resiniferatoxin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Resiniferatoxin, including repackagers and relabelers. The FDA regulates Resiniferatoxin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Resiniferatoxin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Resiniferatoxin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Resiniferatoxin supplier is an individual or a company that provides Resiniferatoxin active pharmaceutical ingredient (API) or Resiniferatoxin finished formulations upon request. The Resiniferatoxin suppliers may include Resiniferatoxin API manufacturers, exporters, distributors and traders.
click here to find a list of Resiniferatoxin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Resiniferatoxin DMF (Drug Master File) is a document detailing the whole manufacturing process of Resiniferatoxin active pharmaceutical ingredient (API) in detail. Different forms of Resiniferatoxin DMFs exist exist since differing nations have different regulations, such as Resiniferatoxin USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Resiniferatoxin DMF submitted to regulatory agencies in the US is known as a USDMF. Resiniferatoxin USDMF includes data on Resiniferatoxin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Resiniferatoxin USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Resiniferatoxin suppliers with USDMF on PharmaCompass.
Resiniferatoxin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Resiniferatoxin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Resiniferatoxin GMP manufacturer or Resiniferatoxin GMP API supplier for your needs.
A Resiniferatoxin CoA (Certificate of Analysis) is a formal document that attests to Resiniferatoxin's compliance with Resiniferatoxin specifications and serves as a tool for batch-level quality control.
Resiniferatoxin CoA mostly includes findings from lab analyses of a specific batch. For each Resiniferatoxin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Resiniferatoxin may be tested according to a variety of international standards, such as European Pharmacopoeia (Resiniferatoxin EP), Resiniferatoxin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Resiniferatoxin USP).
LOOKING FOR A SUPPLIER?
